{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:14:51Z","timestamp":1766171691727,"version":"3.48.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04248-0","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:21:44Z","timestamp":1766125304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Miaomiao","family":"Gou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niansong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingfa","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhikuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanghai","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"4248_CR1","first-page":"221","volume":"46","author":"RS Zheng","year":"2024","unstructured":"Zheng RS, Chen R, Han BF, Wang SM, Li L, Sun KX, Zeng HM, Wei WW, He J (2024) Cancer incidence and mortality in China 2022. Zhonghua Zhong Liu Za Zhi [Chin J Oncol] 46:221\u2013231","journal-title":"Zhonghua Zhong Liu Za Zhi [Chin J Oncol]"},{"key":"4248_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1200\/EDBK_175228","volume":"37","author":"T Irino","year":"2017","unstructured":"Irino T, Takeuchi H, Terashima M, Wakai T, Kitagawa Y (2017) Gastric cancer in Asia: unique features and management. Am Soc Clin Oncol Educ Book 37:279\u2013291","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10294","key":"4248_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27\u201340","journal-title":"Lancet"},{"issue":"11","key":"4248_CR4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P et al (2023) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 24(11):1181\u20131195","journal-title":"Lancet Oncol"},{"issue":"21","key":"4248_CR5","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y et al (2023) Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA 330(21):2064\u20132074","journal-title":"JAMA"},{"key":"4248_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu MZ, Oh DY, Kato K et al (2024) Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ 385:e078876","journal-title":"BMJ"},{"key":"4248_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.28463","author":"X Zhang","year":"2025","unstructured":"Zhang X, Wang J, Wang G et al (2025) First-line sugemalimab plus chemotherapy for advanced gastric cancer: the GEMSTONE-303 randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2024.28463","journal-title":"JAMA"},{"issue":"4","key":"4248_CR8","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.21.01862","volume":"40","author":"JJ Zhao","year":"2022","unstructured":"Zhao JJ, Yap D, Chan YH et al (2022) Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J Clin Oncol 40(4):392\u2013402","journal-title":"J Clin Oncol"},{"issue":"11","key":"4248_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103962","volume":"9","author":"AG Leone","year":"2024","unstructured":"Leone AG, Mai AS, Fong KY et al (2024) Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups. ESMO Open 9(11):103962","journal-title":"ESMO Open"},{"issue":"9","key":"4248_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS et al (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375(9):819\u2013829","journal-title":"N Engl J Med"},{"issue":"10","key":"4248_CR11","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/s41591-018-0173-9","volume":"24","author":"YL Deribe","year":"2018","unstructured":"Deribe YL, Sun Y, Terranova C et al (2018) Author correction: mutations in the SWI\/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med 24(10):1627","journal-title":"Nat Med"},{"issue":"6","key":"4248_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H (2019) Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol 16(6):356\u2013371","journal-title":"Nat Rev Clin Oncol"},{"issue":"6371","key":"4248_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97\u2013103","journal-title":"Science"},{"issue":"26","key":"4248_CR14","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509\u20132520","journal-title":"N Engl J Med"},{"issue":"6280","key":"4248_CR15","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280):1463\u20131469","journal-title":"Science"},{"issue":"7528","key":"4248_CR16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568\u2013571","journal-title":"Nature"},{"issue":"9","key":"4248_CR17","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14(9):985\u2013990","journal-title":"Nat Med"},{"issue":"2","key":"4248_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ccell.2024.11.009","volume":"43","author":"C Alix-Panabi\u00e8res","year":"2025","unstructured":"Alix-Panabi\u00e8res C, Pantel K (2025) Advances in liquid biopsy: from exploration to practical application. Cancer Cell 43(2):161\u2013165","journal-title":"Cancer Cell"},{"key":"4248_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ebiom.2019.04.003","volume":"43","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhao C, Chang L et al (2019) Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. EBioMedicine 43:261\u2013269","journal-title":"EBioMedicine"},{"key":"4248_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16233960","author":"S Tatalovic","year":"2024","unstructured":"Tatalovic S, Doleschal B, Kupferthaler A et al (2024) Circulating tumor DNA (ctDNA) dynamics predict early response to treatment in metastasized gastroesophageal cancer (mGEC) after 2 weeks of systemic treatment. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16233960","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4248_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12967-022-03567-5","volume":"20","author":"W Xi","year":"2022","unstructured":"Xi W, Zhou C, Xu F et al (2022) Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA. J Transl Med 20(1):365","journal-title":"J Transl Med"},{"issue":"1","key":"4248_CR22","doi-asserted-by":"publisher","first-page":"14027","DOI":"10.1038\/s41598-024-63486-x","volume":"14","author":"R Jiang","year":"2024","unstructured":"Jiang R, Cheng X, Li P, Meng E, Wu X, Wu H (2024) Plasma circulating tumor DNA unveils the efficacy of PD-1 inhibitors and chemotherapy in advanced gastric cancer. Sci Rep 14(1):14027","journal-title":"Sci Rep"},{"issue":"1","key":"4248_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-020-01274-7","volume":"19","author":"Y Jin","year":"2020","unstructured":"Jin Y, Chen DL, Wang F et al (2020) The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer 19(1):154","journal-title":"Mol Cancer"},{"key":"4248_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","volume":"4","author":"D Li","year":"2019","unstructured":"Li D, Li X, Zhou WL et al (2019) Genetically engineered T cells for cancer immunotherapy. Signal Transduct Target Ther 4:35","journal-title":"Signal Transduct Target Ther"},{"issue":"19","key":"4248_CR25","doi-asserted-by":"publisher","first-page":"7951","DOI":"10.1073\/pnas.0902728106","volume":"106","author":"K Rubtsova","year":"2009","unstructured":"Rubtsova K, Scott-Browne JP, Crawford F, Dai S, Marrack P, Kappler JW (2009) Many different Vbeta CDR3s can reveal the inherent MHC reactivity of germline-encoded TCR V regions. Proc Natl Acad Sci U S A 106(19):7951\u20137956","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4248_CR26","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1146\/annurev-immunol-042718-041757","volume":"37","author":"P Bradley","year":"2019","unstructured":"Bradley P, Thomas PG (2019) Using T cell receptor repertoires to understand the principles of adaptive immune recognition. Annu Rev Immunol 37:547\u2013570","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"4248_CR27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1158\/0008-5472.CAN-19-1457","volume":"80","author":"LG Cowell","year":"2020","unstructured":"Cowell LG (2020) The diagnostic, prognostic, and therapeutic potential of adaptive immune receptor repertoire profiling in cancer. Cancer Res 80(4):643\u2013654","journal-title":"Cancer Res"},{"issue":"6","key":"4248_CR28","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/j.jid.2017.04.001","volume":"137","author":"TR Matos","year":"2017","unstructured":"Matos TR, de Rie MA, Teunissen M (2017) Research techniques made simple: high-throughput sequencing of the T-cell receptor. J Invest Dermatol 137(6):e131\u2013e138","journal-title":"J Invest Dermatol"},{"key":"4248_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848113","volume":"13","author":"M Wang","year":"2022","unstructured":"Wang M, Gao P, Ren L et al (2022) Profiling the peripheral blood T cell receptor repertoires of gastric cancer patients. Front Immunol 13:848113","journal-title":"Front Immunol"},{"issue":"4","key":"4248_CR30","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","volume":"30","author":"RJ Kelly","year":"2024","unstructured":"Kelly RJ, Landon BV, Zaidi AH et al (2024) Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. Nat Med 30(4):1023\u20131034","journal-title":"Nat Med"},{"issue":"1","key":"4248_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41467-020-20162-8","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Yao Y, Xu Y et al (2021) Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. Nat Commun 12(1):11","journal-title":"Nat Commun"},{"issue":"4","key":"4248_CR32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.annonc.2020.01.014","volume":"31","author":"G Lin","year":"2020","unstructured":"Lin G, Li C, Li PS et al (2020) Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous\u00a0carcinoma. Ann Oncol 31(4):517\u2013524","journal-title":"Ann Oncol"},{"issue":"1","key":"4248_CR33","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1038\/s41467-018-07767-w","volume":"9","author":"Q Jia","year":"2018","unstructured":"Jia Q, Wu W, Wang Y et al (2018) Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun 9(1):5361","journal-title":"Nat Commun"},{"issue":"19","key":"4248_CR34","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","volume":"114","author":"HS Robins","year":"2009","unstructured":"Robins HS, Campregher PV, Srivastava SK et al (2009) Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114(19):4099\u20134107","journal-title":"Blood"},{"issue":"10","key":"4248_CR35","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/2159-8290.CD-17-0256","volume":"7","author":"A Reuben","year":"2017","unstructured":"Reuben A, Gittelman R, Gao J et al (2017) TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence. Cancer Discov 7(10):1088\u20131097","journal-title":"Cancer Discov"},{"issue":"3","key":"4248_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","volume":"28","author":"TV Henriksen","year":"2022","unstructured":"Henriksen TV, Tarazona N, Frydendahl A et al (2022) Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin Cancer Res 28(3):507\u2013517","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4248_CR37","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.21873\/anticanres.12662","volume":"38","author":"M Bassanelli","year":"2018","unstructured":"Bassanelli M, Sioletic S, Martini M et al (2018) Heterogeneity of PD-L1 expression and relationship with biology of NSCLC. Anticancer Res 38(7):3789\u20133796","journal-title":"Anticancer Res"},{"key":"4248_CR38","unstructured":"https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024"},{"key":"4248_CR39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.423","author":"ZS Xiangrui Meng","year":"2025","unstructured":"Xiangrui Meng ZS, Lulu Guan XD, Fan Q, Wang F (2025) Updated results from the phase Ib\/II study of fruquintinib combined with SOX and toripalimab in patients with advanced metastatic gastric\/gastroesophageal junction adenocarcinoma (GC\/GEJC). J clin oncol. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.423","journal-title":"J clin oncol"},{"issue":"16","key":"4248_CR40","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1158\/1078-0432.CCR-22-0630","volume":"28","author":"H Yukami","year":"2022","unstructured":"Yukami H, Kawazoe A, Lin YT, Koyama S, Fukuoka S, Hara H, Takahashi N, Kojima T, Asayama M, Yoshii T, Bando H (2022) Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials. Clin Cancer Res. Clin Cancer Res. 28(16):3480\u20133488","journal-title":"Clin Cancer Res. Clin Cancer Res."},{"key":"4248_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03450-4","author":"L Shen","year":"2025","unstructured":"Shen L, Zhang Y, Li Z et al (2025) First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-024-03450-4","journal-title":"Nat Med"},{"issue":"7","key":"4248_CR42","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41591-024-03007-5","volume":"30","author":"X Gao","year":"2024","unstructured":"Gao X, Ji K, Jia Y et al (2024) Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b\/2 COMPASSION-04 trial. Nat Med 30(7):1943\u20131951","journal-title":"Nat Med"},{"issue":"36","key":"4248_CR43","doi-asserted-by":"publisher","first-page":"433248","DOI":"10.1200\/JCO.2023.41.36_suppl.433248","volume":"41","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Oh DY, Pelster M, Wainberg ZA, Sison EAR, Scott JR, Ronayne J, Wishengrad D, Rhee J, Nuyten DS, Rha SY (2023) EDGE-Gastric Arm A1: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer. J Clin Oncol 41(36):433248","journal-title":"J Clin Oncol"},{"issue":"17","key":"4248_CR44","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1200\/JCO.23.01636","volume":"42","author":"S Hegewisch-Becker","year":"2024","unstructured":"Hegewisch-Becker S, Mendez G, Chao J et al (2024) First-line nivolumab and relatlimab plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma: the phase II RELATIVITY-060 study. J Clin Oncol 42(17):2080\u20132093","journal-title":"J Clin Oncol"},{"issue":"3","key":"4248_CR45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang Y, Kim B, Chan CK, Hahn SM, Weissman IL, Jiang W (2018) Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol 18(3):195\u2013203","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"4248_CR46","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan KA, Kerbel RS (2018) Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol 15(5):310\u2013324","journal-title":"Nat Rev Clin Oncol"},{"issue":"7517","key":"4248_CR47","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"The Cancer Genome Atlas Research Network","year":"2014","unstructured":"The Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517):202\u2013209","journal-title":"Nature"},{"issue":"9","key":"4248_CR48","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","volume":"1","author":"SV Bratman","year":"2020","unstructured":"Bratman SV, Yang S, Iafolla M et al (2020) Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer 1(9):873\u2013881","journal-title":"Nat Cancer"},{"issue":"6282","key":"4248_CR49","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey SC, Tong L, Li Y et al (2016) MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352(6282):227\u2013231","journal-title":"Science"},{"issue":"10","key":"4248_CR50","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/cac2.12074","volume":"40","author":"N Li","year":"2020","unstructured":"Li N, Yuan J, Tian W, Meng L, Liu Y (2020) T-cell receptor repertoire analysis for the diagnosis and treatment of solid tumor: a methodology and clinical applications. Cancer Commun (Lond) 40(10):473\u2013483","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"4248_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/2326-6066.CIR-18-0136","volume":"7","author":"SA Hogan","year":"2019","unstructured":"Hogan SA, Courtier A, Cheng PF et al (2019) Peripheral blood TCR repertoire profiling may facilitate patient stratification for immunotherapy against melanoma. Cancer Immunol Res 7(1):77\u201385","journal-title":"Cancer Immunol Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04248-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04248-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04248-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:01:46Z","timestamp":1766170906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04248-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4248"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04248-0","relation":{},"ISSN":["1432-0851"],"issn-type":[{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study was approved by the independent ethics committee of the Chinese PLA General Hospital, and all the authors consented to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the authors had consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"12"}}